OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for RC211511L3V

BARD1 (NM_000465) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type:	Lentiviral Particles
Product Name:	BARD1 (NM_000465) Human Tagged ORF Clone Lentiviral Particle
Symbol:	BARD1
Mammalian Cell Selection:	Puromycin
Vector:	pLenti-C-Myc-DDK-P2A-Puro (PS100092)
Tag:	Myc-DDK
ACCN:	NM_000465
ORF Size:	2331 bp
ORF Nucleotide Sequence:	The ORF insert of this clone is exactly the same as(RC211511).
OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
RefSeq:	NM_000465.1
RefSeq Size:	2530 bp
RefSeq ORF:	2334 bp
Locus ID:	580
UniProt ID:	Q99728
Cytogenetics:	2q35
Domains:	BRCT, ANK
Protein Families:	Druggable Genome
MW:	86.5 kDa

View online »

Gene Summary: This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]